Browsing Tag
Crystalys Therapeutics
1 post
Crystalys Therapeutics doses first patients in Fortress Biotech’s global Phase 3 gout trial of Dotinurad, targeting safer uric acid control
Find out how Fortress Biotech’s Dotinurad is advancing in global Phase 3 trials and why it could redefine gout therapy worldwide.